Trustees of Princeton University’s Ocular Therapeutix OCUL Stock Holding History

Trustees of Princeton University’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$629K	Buy	+30,410	New	+$452K	0.94%	5

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Trustees of Princeton University's OCUL Position: Q4 2020 in Review

Trustees of Princeton University opened a new position in Ocular Therapeutix (OCUL) in Q4 2020: 30,410 shares worth $629K. The stake represents 0.94% of the portfolio and ranks #5 among its holdings.

149 funds tracked by Wall St. Rank hold OCUL as of Q4 2020.

Trustees of Princeton University held 30,410 shares of Ocular Therapeutix worth $629K as of Q4 2020.
Ocular Therapeutix was a new Trustees of Princeton University position in Q4 2020.
Ocular Therapeutix made up 0.94% of Trustees of Princeton University's portfolio in Q4 2020, its #5 holding.
149 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2020.

Based on Trustees of Princeton University's 13F filing for Q4 2020, filed 9 Feb 2021.